These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28613442)

  • 1. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
    Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S
    Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
    Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
    Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
    Deeks ED; Keating GM
    Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
    Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
    Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
    J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
    Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
    Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
    Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.